Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a stock price increase of over 4%, currently trading at 14.21 HKD with a transaction volume of 59.4 million HKD, following the announcement of its new drug's inclusion in the priority review list by the National Medical Products Administration (NMPA) [1] Group 1 - The company is developing a first-class new drug, Tysun (TY-9591), which targets adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have specific EGFR mutations and CNS metastasis [1] - The NMPA's decision to include TY-9591 in the priority review list is a significant milestone for the company, potentially expediting the drug's approval process [1] - The intended indication for TY-9591 is for first-line treatment in patients with EGFR exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations [1]
港股异动 | 同源康医药-B(02410)午后涨超4% 甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评